Evidence map›Paper›PMID 25065704›Full record

ReviewUrologic oncology2015

Summary of the 8th Annual Bladder Cancer Think Tank: Collaborating to move research forward.

Andrea B Apolo, Vanessa Hoffman, Matthew G Kaag, David M Latini, Cheryl T Lee, Jonathan E Rosenberg, Margaret Knowles, Dan Theodorescu, Bogdan A Czerniak, Jason A Efstathiou and 12 more

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Urologic oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Impact of serum vitamin D level on risk of bladder cancer: a systemic review and meta-analysis.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015
    Pooled it
  2. Managing female sexual dysfunction.Urologic oncology · 2022
    Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 17 institutions in 4 countries.

Andrea B ApoloGenitourinary Malignancies Branch, National Cancer Institute, Bethesda, MD.
Vanessa HoffmanBladder Cancer Advocacy Network, Bethesda, MD.
Matthew G KaagDepartment of Urology, Penn State Hershey Medical Center, Hershey, PA.
David M LatiniDepartment of Urology, Baylor College of Medicine, Houston, TX.
Cheryl T LeeDepartment of Urology, University of Michigan Health System, Ann Arbor, MI.
Jonathan E RosenbergDepartment of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY.
Margaret KnowlesLeeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK.
Dan TheodorescuUniversity of Colorado Cancer Center, Denver, CO.
Bogdan A CzerniakDepartment of Pathology, MD Anderson Cancer Center, Houston, TX.
Jason A EfstathiouHarvard Medical School, Massachusetts General Hospital, Boston, MA.
Matthew L AlbertDepartment of Immunology, Institut Pasteur, Paris, France.
Srikala S SridharDepartment of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
Vitaly MargulisDepartment of Urology, University of Texas Southwestern Medical Center, Dallas, TX.
Surena F MatinDepartment of Urology, MD Anderson Cancer Center, Houston, TX.
Matthew D GalskyDepartment of Medical Oncology, Mount Sinai Hospital, New York, NY.
Donna HanselDepartment of Pathology, University of California, La Jolla, San Diego, CA.
Ashish M KamatDepartment of Urology, MD Anderson Cancer Center, Houston, TX.
Thomas W FlaigUniversity of Colorado Cancer Center, Denver, CO.
Angela B SmithDepartment of Urology, University of North Carolina, Chapel Hill, NC.
Edward MessingDepartment of Urology, University of Rochester Medical Center, Rochester, NY.
Diane Zipursky QualeBladder Cancer Advocacy Network, Bethesda, MD.
Yair LotanDepartment of Urology, University of Texas Southwestern Medical Center, Dallas, TX. Electronic address: yair.lotan@utsouthwestern.edu.
The University of Texas MD Anderson Cancer Center · USBladder Cancer Advocacy Network · USThe University of Texas Southwestern Medical Center · USUniversity of Colorado Denver · USBaylor College of Medicine · USHarvard University · USIcahn School of Medicine at Mount Sinai · USInstitut Pasteur · FRMemorial Sloan Kettering Cancer Center · USMichigan Medicine · USNational Institutes of Health · USPennsylvania State University · USPrincess Margaret Cancer Centre · CAUniversity of California, San Diego · USUniversity of Leeds · GBUniversity of North Carolina at Chapel Hill · USUniversity of Rochester Medical Center · US

Funding

Bladder Cancer ProgramZIABC011351 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI APOLO, ANDREA · 2010 to 2025
$9.4M
Intramural NIH HHS ZIA BC011351
6 · The paper itself

Abstract

objectivesThe 8th Annual Bladder Cancer Think Tank (BCAN-TT) brought together a multidisciplinary group of clinicians, researchers, and patient advocates in an effort to advance bladder cancer research. METHODS AND MATERIALS: With the theme of "Collaborating to Move Research Forward," the meeting included three panel presentations and seven small working groups.

resultsThe panel presentations and interactive discussions focused on three main areas: gender disparities, sexual dysfunction, and targeting novel pathways in bladder cancer. Small working groups also met to identify projects for the upcoming year, including: (1) improving enrollment and quality of clinical trials; (2) collecting data from multiple institutions for future research; (3) evaluating patterns of care for non-muscle-invasive bladder cancer; (4) improving delivery of care for muscle-invasive disease; (5) improving quality of life for survivors; (6) addressing upper tract disease; and (7) examining the impact of health policy changes on research and treatment of bladder cancer.

conclusionsThe goal of the BCAN-TT is to advance the care of patients with bladder cancer and to promote collaborative research throughout the year. The meeting provided ample opportunities for collaboration among clinicians from multiple disciplines, patients and patient advocates, and industry representatives.

Indexed as

AnimalsFemaleHealth PolicyHumansMaleSex FactorsUrinary Bladder NeoplasmsBCANBladder cancerGender disparitiesSexual dysfunctionTargeted therapiesThink TankWorking groups

Identifiers

PMID25065704
PMCPMC6776416
OpenAlexW2096543518

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.